Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Frontier: COVID-19 Crisis Opens Door For Dexcom, Abbott To Bring CGMs Into Hospitals For First Time

Executive Summary

Dexcom and Abbott’s permission by US regulators to bring their continuous glucose monitoring devices directly to hospitals for remote monitoring of COVID-19 patients could open up a new market opportunity post-pandemic.

You may also be interested in...



Exec Chat: Dexcom CEO Kevin Sayer Talks About Access, Growth, Resiliency During Pandemic

Full steam ahead: Dexcom brings its flagship G6 CGM to veterans, creates first registry for in-hospital use and signs collaboration with University of Virginia.

Abbott’s Freestyle Libre 2 Gains Medicare Coverage

FreeStyle Libre 2 is the only integrated continuous glucose monitoring system that continuously measures the user's blood glucose without fingersticks.

Dexcom’s Q2 Earnings Exceed Wall Street Expectations; Holds G7 Launch

Dexcom expects 2020 revenues to reach $1.85bn driven by new patient adoption of its CGM device, but will not launch its next-gen G7 this year. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel